A prospective randomised trial of cyclosporin and methotrexate versus cyclosporin, methotrexate and prednisolone for prevention of graft‐versus‐host disease after HLA‐identical sibling marrow transplantation for haematological malignancy

Australian and New Zealand Journal of Medicine

Volumn 21, Issue 6, 1991, Pages 850-856

  Atkinson, K ^a   Biggs, J ^a   Concannon, A ^a   Dodds, A ^a   Young, S ^a   Wilson, F ^a   Ashby, M ^a   Downs, K ^a  

^a ST VINCENT S HOSPITAL   (Australia)

Author keywords

bone marrow transplants; cyclosporin; Graft versus host disease; haematological malignancy; HLA identical sibling; methotrexate; prednisolone

Indexed keywords

CYCLOSPORIN; HLA ANTIGEN; METHOTREXATE; PREDNISOLONE;

ACUTE DISEASE; ADOLESCENT; ADULT; ARTICLE; BONE MARROW TRANSPLANTATION; CHRONIC DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG COMBINATION; FAMILY; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOLOGY; INCIDENCE; LEUKEMIA; MALE; MORTALITY; MYELODYSPLASTIC SYNDROME; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; SURVIVAL; TREATMENT OUTCOME; TUMOR RECURRENCE;

ACTUARIAL ANALYSIS; ACUTE DISEASE; ADOLESCENT; ADULT; BONE MARROW TRANSPLANTATION; CHRONIC DISEASE; COMPARATIVE STUDY; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FAMILY; FEMALE; GRAFT VS HOST DISEASE; HLA ANTIGENS; HUMAN; INCIDENCE; LEUKEMIA; MALE; METHOTREXATE; MIDDLE AGE; MYELODYSPLASTIC SYNDROMES; NEOPLASM RECURRENCE, LOCAL; PREDNISOLONE; PROSPECTIVE STUDIES; SUPPORT, NON-U.S. GOV'T; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0026271647     PISSN: 00048291     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.1991.tb01406.x     Document Type: Article

References (19)

1. el al. Cyclosporine as prophylaxis for graft‐versus‐host disease: a randomised study in patients undergoing bone marrow transplantation for acute non lymphoblastic leukemia
2. A prospective randomised trial of cyclosporin versus methotrexate after HLA‐identical sibling marrow transplantation for patients with acute leukemia in first remission: analysis 2.5 years after last patient entry
3. A randomised trial comparing the use of cyclosporin and methotrexate for graft‐versus‐host disease prophylaxis in bone marrow transplant recipients with haematological malignancies
4. Marrow transplantation for leukemia. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft‐versus‐host disease after marrow transplantation for leukemia
5. Marrow transplantation for severe aplastic anemia. Methotrexate alone compared to a combination of methotrexate and cyclosporine for prevention of acute graft‐versus‐host disease
6. Preparative regimes for marrow transplantation containing Busulphan are associated with haemorrhagic cystitis and hepatic veno‐occlusive disease, but a short duration of leucopenia and little oro‐pharyngeal mucositis
7. Female marrow donors increase the risk of acute graft‐versus‐host disease: effect of donor age and parity and analysis of cell subpopulations in the donor marrow inoculum
8. Risk factors for acute graft‐versus‐host disease
9. Clinical manifestations of graft‐versus‐host disease in human recipients of marrow from HLA‐matched sibling donors
10. Histopathology of graft‐versus‐host reaction (GVHR) in human recipients from HLA‐matched sibling donors
11. Chronic graft‐versus‐host syndrome in man. A long term clinicopathological study of 20 Seattle patients
12. Chronic graft‐versus‐host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression
13. Non‐parametric estimation from incomplete observations
14. Avascular necrosis of femoral head secondary to corticosteroid therapy for graft‐versus‐host disease after marrow transplantation: effective therapy with hip arthroplasty
15. Graft‐versus‐leukemia reactions after bone marrow transplantation
16. A comparative study of T cell depleted and non‐depleted marrow transplantation for haematological malignancy
17. Marrow transplantation for the treatment of chronic myelogenous leukemia
18. Remission induction in non‐Hodgkin's lymphoma with reshaped human monoclonal antibody Campath 1H
19. A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin